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Abstract 27 
A spring-dashpot system based on the Voigt model was developed to model the correlation 28 
between abdominal respiratory motion and tumor motion during lung radiotherapy. The 29 
model was applied to clinical data comprising 52 treatment beams from 10 patients, treated 30 
on the Mitsubishi Real-Time Radiation Therapy system, Sapporo, Japan. In Stage 1, model 31 
parameters were optimized for individual patients and beams to determine reference values 32 
and to investigate how well the model can describe the data. In Stage 2, for each patient the 33 
optimal parameters determined for a single beam were applied to data from other beams to 34 
investigate whether a beam-specific set of model parameters is sufficient to model tumor 35 
motion over a course of treatment.  36 
In Stage 1 the baseline root mean square (RMS) residual error for all individually-optimized 37 
beam data was 0.90 ± 0.40 mm. In Stage 2, patient-specific model parameters based on a 38 
single beam were found to model the tumor position closely, even for irregular beam data, 39 
with a mean increase with respect to Stage 1 values in RMS error of 0.37 mm. On average 40 
the obtained model output for the tumor position was 95% of the time within an absolute 41 
bound of 2.0 mm and 2.6 mm in Stage 1 and 2, respectively. 42 
The model was capable of dealing with baseline, amplitude and frequency variations of the 43 
input data, as well as phase shifts between the input tumor and output abdominal signals. 44 
These results indicate that it may be feasible to collect patient-specific model parameters 45 
during or prior to the first treatment, and then retain these for the rest of the treatment period. 46 
The model has potential for clinical application during radiotherapy treatment of lung tumors.  47 
 48 
Keywords:   spring-dashpot model, radiotherapy, lung tumor modeling, respiration, 49 
differential equation 50 
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1. Introduction 51 
Lung cancer was the most commonly diagnosed cancer worldwide in 2008, with an 52 
incidence rate of over 1.5 million new cases, or 12 % of the total new cancer diagnoses1. It 53 
was also the most common cause of death from cancer, accounting for 17% of all cancer 54 
deaths. Radiation therapy is a common modality for lung cancer treatment, however 55 
treatment efficacy is limited by the motion of the lungs during respiration2, which is primarily 56 
driven by diaphragm motion, and to a lesser extent by chest motion. The magnitude of lung 57 
tumor motion depends on patient-specific breathing and tumor characteristics, and is usually 58 
most pronounced along the superior-inferior (SI) axis, compared to the anterior-posterior 59 
(AP) and lateral directions3. One study, which included 39 patients treated with the Real-60 
Time Radiation Therapy system in Sapporo, Japan, found a median tumor movement of 1.1 61 
mm, 2.3 mm and 5.4 mm in lateral, AP and SI direction, respectively4.  62 
Typically, for lung tumors the clinical target volume (CTV) is enlarged to the internal target 63 
volume (ITV) with the intent of ensuring sufficient tumor coverage in the presence of motion5. 64 
This strategy can result in excessive irradiation of surrounding healthy tissue, or marginal 65 
miss of the tumor6. The high doses required for tumor control are close to or above the 66 
tolerance level for healthy tissues, resulting in increased side effects, or requiring a reduction 67 
in dose to the tumor, decreasing tumor control probability (TCP)7, 8. In this way, 68 
compensating for the presence of respiratory motion of lung tumors can improve the 69 
therapeutic ratio and thus survival rates9. 70 
One means to compensate for tumor motion is by means of real-time tumor tracking and 71 
motion compensation8, 10-14. Motion tracking is complicated by variations in baseline, 72 
frequency and oscillatory amplitude and form, despite the overall superficial regularity of 73 
respiratory motion. These effects can differ widely between patients but can also vary over 74 
the course of treatment of a single patient7. Methods to suppress such variability include 75 
abdominal compression to reduce tumor mobility, breath control techniques (active or 76 
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passive) and respiratory gating of irradiation3, 7, 15-19, with the latter usually based on external 77 
surrogate motion. All of these techniques have some limitations, such as the need for active 78 
patient cooperation, consistent ability to maintain total lung capacity20, or a lengthened 79 
treatment time for gated therapy due to the required beam-off periods.    80 
Modeling of the respiratory-induced lung tumor motion can facilitate dynamic tracking and 81 
compensation for real-time and gated treatments4, 7, 8, 19. Direct tumor tracking systems may 82 
use portal imaging10, 13, 21, 22 or implanted fiducial markers in the tumor, in conjunction with a 83 
diagnostic x-ray imaging system20, 23, 24, but this continuous imaging can impart a 84 
considerable radiation dose which is not always clinically justifiable25.  85 
By contrast, indirect tumor tracking systems use internal or external surrogates to obtain 86 
tracking signals. A model is then required to relate the surrogate to tumor motion. Examples 87 
of external respiratory surrogates are a spirometer, strain gauge or abdominal markers20, 88 
while an internal surrogate can be the diaphragm motion26. Such indirect approaches require 89 
the relationship between surrogate and internal tumor motion to be consistent and well 90 
correlated27. The benefits of indirect tracking include the elimination of risks associated with 91 
changes in the relationship between tumor and implanted marker during radiotherapy4, 92 
fiducial implantation, extra radiation doses, and direct tracking failures. Most models 93 
correlating surrogate data to tumor motion have been so-called ‘black box’ or ‘grey box’ 94 
approaches, for which the internal behavior of the physical system is not or only partially 95 
known, respectively. These models consider the input and output data, but not the exact 96 
physical relationship between them. Various approaches of this form include linear 97 
correspondence models9, 28, composites of baseline drift, frequency variation, fundamental 98 
pattern change and random observation noise7, characterization of the motion with a 99 
piecewise linear model of defined stages of the breathing cycle29, state-based probabilistic 100 
models30, least-squares parameter estimation and systems identification3 or adaptive neural 101 
networks31. These models generally require a large amount of sample data which 102 
encompasses the range of possible relationships between the input and output states. Many 103 
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of the previous external surrogate models tend to deal poorly with irregularities in the 104 
breathing pattern, such as baseline drift or a hysteresis31, a lag or phase shift between 105 
internal and external motions27, 32, 33, and usually have a strong dependence on tumor and 106 
marker locations, motion dimensions and type of breathing pattern3, 4, 28. One of the more 107 
promising models is the model by Cervino et al.26 using an internal surrogate signal of the 108 
diaphragm; however the practical benefits of using an external signal warrant further 109 
investigation into external abdominal surrogates.  110 
A more physical approach to the problem models lung motion as a contact problem of 111 
elasticity theory by describing the physiology of breathing using elastic constants to directly 112 
model the lung tissue34. A different approach was explored by Wilson and Meyer35, 36 who 113 
presented a comprehensive physical 3D system of springs and dashpots to model the 114 
correlation of an external abdominal respiratory signal and the lung tumor motion, rather 115 
than directly modeling the actual lung tissue24. Wilson and Meyer showed mathematically 116 
that it is possible to formally simplify the three-dimensional model to a one-dimensional 117 
model when SI motion of the tumor dominates.   118 
To overcome some of the physical intrinsic limitations for the practical application of the 119 
above approach, the first aim of this paper was to refine the Wilson and Meyer model in the 120 
one-dimensional realm. The relationship of lung tumor and external abdominal marker 121 
movement is considered for the primary dimension of motion, i.e. the SI and AP direction of 122 
the tumor and abdominal signal, respectively. The second objective was to apply the refined 123 
model to a large and realistic clinical data set of tumor motion from a cohort of lung cancer 124 
patients treated with the Mitsubishi Real-Time Radiation Therapy system in Sapporo, Japan 125 
to investigate the model behavior on an intra- and inter-patient specific basis. 126 
 127 
2. Material and Methods 128 
2.1 Mathematical model 129 
6 
 
Following the methodology of Wilson & Meyer35, we model the correlation between the 130 
surrogate data provided by abdominal motion and the target data of the lung tumor motion 131 
with a pseudo-mechanical system. This system is composed of springs and dashpots, the 132 
latter providing a damping effect. In general, a spring-dashpot unit can be composed of 133 
springs and dashpots in series, parallel, or some combination thereof. Three of the most 134 
frequently-used configurations in other applications are shown in Figure 1. The full three-135 
dimensional system of Wilson & Meyer (2009) featured a Voigt unit able to act in each 136 
Cartesian direction of motion0F 1.  137 
 138 
 139 
Figure 1: (a) Maxwell model (b) Voigt model (c) Standard Linear Solid model. S 140 
denotes a spring and d denotes a dashpot.  141 
 142 
Asymptotic analysis35 shows that when the SI motion of the tumor is dominant the motion is 143 
well-modeled by a single Voigt unit acting in the SI direction, with the tumor attached at one 144 
end and the abdominal system providing input at the other. It is this pseudo-one dimensional 145 
                                                          
1 Note that these were incorrectly drawn in the Wilson & Meyer paper as Maxwell units. 
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class of tumor motion which we consider in this paper. In the following condensed derivation, 146 
all variables and parameters are non-dimensional. 147 
The variable x is the tumor displacement from a resting equilibrium position in the SI 148 
direction. The Hookean spring has associated parameter ω , while the dashpot, 149 
characterized by the parameter λ provides a retarding force directly proportional to the tumor 150 
velocity. Although the dominant time-dependent abdominal motion, f(t), is in the AP direction 151 
perpendicular to the dominant tumor motion direction, this component of the abdominal 152 
signal is linearly scaled and used as input to the model. This forcing input signal, x*(t), is 153 
therefore related to the measured data by fx δ=* , with the scale factor δ being determined 154 
under optimization. This approach reduces the dimension of the parameter space of Wilson 155 
& Meyer by one, and also allows a wider range of parameter values to be studied, both of 156 
which enable the model to be more readily optimized.  157 
Following Wilson & Meyer35 but with the above notation, the tumor motion is given by 158 
 fx
dt
dx
dt
xd δωλ +−−= 22
2
2  (1) 159 
The model will be shown to hold for all patients in this class of tumor motion, with values of 160 
the parameter triplet ( δλω ,, ) derived from a “training” subset of patient data, and 161 
successfully applied to model the remaining data. 162 
 163 
2.2 Numerical approach 164 
Equation (1) was rewritten as two coupled first-order ordinary differential equations, which 165 
were solved for each set of training data using the MATLAB™ differential equation solver 166 
ode45, which is recommended for non-stiff problems37. The resulting output data was 167 
optimized with respect to the model parameter triplet ( δλω ,, ) using the MATLAB 168 
fminsearch routine in combination with a cost function: an iterative process used to find the 169 
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minimum of the root mean squared error (RMS) (2) between the measured tumor position 170 
data, X, and the model output values, x (at each time step, n).  171 
( ) 2
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1
2







 −
= ∑ =
n
xX
RMS
n
i  (2) 172 
The algorithm starts with an initial estimate of the triplet based on the model characterization 173 
in Wilson & Meyer and proceeds via a process of unconstrained non-linear optimization with 174 
a Simplex search method. Optimization is initially patient- and beam-specific and is based on 175 
a set of “training” data constituting approximately 2 minutes of patient data. The algorithm 176 
terminates when the RMS error is less than 10-3 or when a maximum number of 100 177 
iterations have been reached.  178 
In Stage 1 of our work, optimized parameters obtained in this way are used to model the 179 
tumor motion via numerical solutions to equation (1) for each beam to obtain reference 180 
values. We refer to this stage as ‘optimized’. 181 
In Stage 2 ( ‘non-optimized’) we take the optimized parameters from a single beam – e.g. 182 
Day 1, Beam 1– and use these to model the tumor motion via (1) for that patient's 183 
respiratory data obtained from other beams on the same day and consecutive days. The 184 
comparison between the predicted tumor position, x, and the clinical data, X, is presented 185 
and discussed in sections 3 and 4. 186 
 187 
2.3 Clinical data 188 
The clinical data consists of 3D internal fiducial-based motion obtained using radiopaque 189 
fiducial markers implanted and visualized in real-time using stereoscopic diagnostic x-ray 190 
fluoroscopy, collected using a Mitsubishi Real-Time Radiation Therapy system, at the 191 
Nippon Telegraph and Telephone Corporation Hospital, Sapporo, Japan27. This was 192 
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obtained simultaneously with 1D external abdominal motion, collected on an independent 193 
co-ordinate system using a laser based AZ-733V "RespGate" made by Anzai Medical, 194 
Tokyo, Japan.  The data set consisted of motion results from eleven patients (patient 1-11) 195 
with lung cancer at various sites, with a total of 171 treatment beams for up to ten 196 
consecutive treatment fractions (day 1-10) and four beam configurations per fraction (beam 197 
1-4) (1F 2). The patients were not a random sample of the general lung cancer population, but 198 
were selected on the basis of an estimated internal marker motion of more than 10 mm peak 199 
to peak (SI, lateral or AP direction). The data show phase shifts of the internal-external data 200 
(one signal lagging the other)32, 33 in the SI direction that are mostly between 100 and 200 201 
ms. 202 
The data were not acquired in a common coordinate system with absolute spatial co-203 
ordinates and therefore they could not be normalized to a common reference point.  Spatial 204 
baselines for the tumor and abdominal markers were defined by normalizing on the mean of 205 
each beam data. 206 
For baseline values in Stage 1 the model was initially applied to data from 52 treatment 207 
beams from 10 patients: beam 1 data for all days for all patients (as this type of data was 208 
available for all patients), as well as all beams for patients 1-3. More detailed analysis was 209 
then carried out on representative individual patients: one whose model performance was 210 
close to the mean of all patients (Patient 7); one with relatively poor model performance 211 
(Patient 8); and one with excellent model performance (Patient 10). 212 
In the second stage, for each patient the optimal parameters determined for an arbitrarily 213 
chosen single beam were applied to data from other beams and treatment days to 214 
investigate whether a beam-specific set of model parameters is adequate to model tumor 215 
motion over a course of treatment.  216 
                                                          
(2) Patient 5 had eight fractions, then a further four two months later.  The analysis was kept 
consistent. The data for patient 11 were unreliable and not included. 
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We also investigate the ability of the model to adapt to irregularities in the clinical data such 217 
as unclear tracking data, missing data points, baseline drift and amplitude and frequency 218 
variation. 219 
 220 
3. Results 221 
3.1 Stage 1 222 
Applying the optimization algorithm to the data from the 52 clinical treatment beams with the 223 
initial estimate parameter triplet (ω, λ, δ) = (10, 5, 200) gave, on average, a root mean 224 
square error of 0.90 mm (2 s.f.) and a standard deviation of 0.40 mm between the modeled 225 
position and the tumor motion in the superior-inferior direction. The best result from all the 226 
beam data modeled, Patient 4, Day 1, Beam 1, had an RMS error of 0.38 mm. An overview 227 
of the RMS errors for all patients is shown in Figure 2. 228 
The number of iterations required for optimization varied considerably with each beam but 229 
was generally less than 100 iterations. A representative example (patient 7) of beam data 230 
and the model results with a RMS of 0.69 mm is shown in Figure 3, with optimized 231 
parameters ω = 10.12, λ = 5.27, δ = 197.91. 232 
The linear relationship between the position predicted by the model and the actual tumor 233 
location was investigated, and the regression correlation coefficient was calculated for each 234 
beam studied. The mean correlation from all 52 beams was 0.96 with standard deviation of 235 
0.03, which would indicate the existence of strong linear relationships. A graphical analysis 236 
of one beam each for the three representative patients is shown in the top row of Figure 4. 237 
 238 
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Figure 2: Average root mean square error (mm) between model output and clinical data for 240 
each patient. Representative patients 7, 8 and 10 used for further analysis are marked as 241 
‘mean’, poor’ and ‘excellent’, respectively. Note that the number of beams included to 242 
calculate the RMS errors varies between patients. 243 
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 245 
Figure 3: The clinical data and model output, showing breathing pattern, tumor motion, and 246 
model output for Patient 7, Day 4, Beam 1. The lower figure shows a close-up view of part of 247 
the tumor data and model output. 248 
 249 
Additionally, we considered the residual vectors for each beam, which appeared visually to 250 
have a normal-like distribution, although a more rigorous testing of these vectors revealed 251 
that only four beams were sufficiently normal to satisfy the Jarque-Bera38 test. The bottom 252 
row of Figure 4 shows the histograms of three beams. Note that the best fitting probability 253 
distribution is scaled to the area of the histograms. The full width at half maximum was 1.6 254 
mm, 3.9 mm and 1.2 mm for patients 7, 8 and 10, (mean, poor, excellent), respectively. 255 
 256 
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 257 
Figure 4: Regression plots and residual histograms for three beams: “mean” Patient 7, Day 258 
4, Beam 1 (left); “poor” Patient 8, Day 1, Beam 1 (center); “excellent” Patient 10, Day 1, 259 
Beam 1 (right). 260 
 261 
For clinical applications, a major concern is the proportion of time, which we term the 262 
residency, for which the model output is within a small distance of the actual tumor position, 263 
i.e. within the treatment margin. The residency of the 52 beams was calculated for bounds 264 
on the absolute difference in positions of 1, 2, 3, 4, 5 mm. The residencies from Patients 7, 8 265 
and 10, and all 52 beams are shown in Table 1. As can be seen from the table, to be 266 
resident 95% of the time a bound of 2 mm is required on average. In the second stage the 267 
parameter results obtained from optimizing the Day 1, Beam 1 data for each patient were 268 
applied to other beams and days for that patient in lieu of optimizing the data from each 269 
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beam independently (Stage 1). There was an average increase in RMS error of 0.37 mm. 270 
Results are shown in Table 2.  271 
When the robustness of the model was examined with respect to the linear relationship 272 
between the tumor position and model prediction, the mean correlation coefficient of the 52 273 
beams was 0.96, the same value as when each beam was optimized independently. 274 
There was a drop in residency in this second stage as can be seen from Table 3. This time a 275 
band width of 2.6 mm was required on average, an increase of 0.60 mm, for 95% residency. 276 
 277 
Table 1: Residency analysis for Patient 7, Patient 8, Patient 10 and all 52 beams studied 278 
(Stage 1).  279 
Band Width 1 mm 2 mm 3 mm 4 mm 5 mm 
Patient 7 72% 97% 99% 100% 100% 
Patient 8 50% 84% 96% 99% 99% 
Patient 10 92% 99% 100% 100% 100% 
All 52 beams 76% 95% 99% 100% 100% 
 280 
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Table 2: Comparison of RMS error results for Patient 7, Patient 8, Patient 10 and all 52 281 
beams studied. 282 
 Average RMS error 
 Stage 1: optimized Stage 2: non-
optimized 
Difference 
Patient 7 0.91 mm 1.16 mm 0.25 mm 
Patient 8 1.50 mm 1.70 mm 0.20 mm 
Patient 10 0.58 mm 0.70 mm 0.12 mm 
All 52 beams 0.90 mm 1.27 mm 0.37 mm 
 283 
Table 3: Residency analysis for Patient 7, Patient 8, Patient 10 and all 52 beams without 284 
further optimization (i.e. Stage 2), using Day 1, Beam 1 parameters. 285 
 286 
Band Width 1 mm 2 mm 3 mm 4 mm 5 mm 
Patient 7 62% 91% 99% 100% 100% 
Patient 8 42% 77% 94% 99% 99% 
Patient 10 85% 99% 100% 100% 100% 
All 52 beams 56% 88% 98% 99% 100% 
 287 
3.1.1 Detailed analysis of Patients 7, 8, and 10 288 
The means in Table 2 for patients 7, 8, and 10 were obtained from a subset of data available 289 
for those patients. Now we consider all available and reliable data for patients 7, 8, and 10 to 290 
determine whether our initial use of a subset of data biased the results shown in Table 2. In 291 
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Table 4 we show that no such bias exists, because when all available and reliable3 beam 292 
data for Patient 7, Patient 8 and Patient 10 were analyzed, the RMS error and residency 293 
results for Patients 7 and 8 calculated from optimized results from all available beam data 294 
are close to the values shown in Table 2. The changes in the mean correlation coefficients 295 
for Patients 7 and 8 were negligible (about 0.96 in all cases) whereas the mean correlation 296 
coefficient for Patient 10 dropped from 0.99 to 0.98 when all available beam data were 297 
analyzed, in both Stage 1 and Stage 2. 298 
 299 
Table 4: Comparison results for all available and reliable data for Patient 7, Patient 8, 300 
Patient 10, and all 52 beams studied. 301 
 Average RMS error Band width for 95% residency 
 Stage 1 
optimized 
Stage 2 
non-optimized 
Stage 1 
optimized 
Stage 2 
non-optimized 
Patient 7 0.95 mm 1.36 mm 2.1 mm 2.9 mm 
Patient 8 1.61 mm 1.87 mm 3.0 mm 3.5 mm 
Patient 10 0.84 mm 0.95 mm 1.7 mm 2.0 mm 
All 52 beams 0.90 mm 1.27 mm 2.0 mm 2.6 mm 
 302 
                                                          
3One beam was omitted for patient 10 because it contained a substantial amount of missing 
data, and obviously spurious measurements. 
17 
 
3.1.2 Sensitivity of optimization for different days.  303 
To test the sensitivity to beam and day parameter optimization, non-optimized results were 304 
obtained for Patients 7, 8, and 10 using the parameters obtained from optimizing the Day 3, 305 
Beam 2 data, a choice made arbitrarily.  The change in the average RMS error and the band 306 
width required for 95% residency was small as can be seen from Table 5 below, and there 307 
was no change in the mean correlation results. This would indicate that different parameter 308 
sets obtained from different beams for the same patient give adequate results. 309 
 310 
Table 5: Results for all available and reliable data for Patient 7, Patient 8, and Patient 10 311 
optimized using Day 3, Beam 2 parameters. 312 
 Average RMS error Mean correlation 
coefficient 
Band width for 95% 
residency 
Patient 7 1.17 mm 0.96 2.5 mm 
Patient 8 1.91 mm 0.96 3.6 mm 
Patient 10 0.95 mm 0.98 2.0 mm 
 313 
3.4 Irregular beam data 314 
The model was capable of dealing with data containing irregularities such as missing data 315 
covering several seconds (poor tracking of the abdominal motion), spikes in the amplitude of 316 
tumor motion and baseline drift. Figure 5 shows an example of the model applied to data 317 
containing some initial baseline drift of the breathing signal, a period of missing data, and an 318 
unusual rapid variation in amplitude, or "spike". These data problems are important 319 
considerations for modeling lung tumor motion to ensure that errors are not avoidably high. 320 
 321 
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Figure 5: Breathing data (top) and tumor data and model output (middle) for Patient 8, Day 323 
2, Beam 1. Labeled are a lengthy period of missing data and a "spike" in the data. The solid 324 
line for the model data is an interpolation between points and therefore does not represent 325 
actual model output; specifically, the model makes no predictions during periods of missing 326 
breathing data. An initial baseline drift is also apparent. The lower figure shows in greater 327 
resolution how the model copes with the data spike. 328 
 329 
This incomplete data gives a useful clarification of the functioning of the model. The model 330 
was not designed to predict tumor motion in the absence of breathing data, only in the 331 
absence of tumor data. Thus we see that when the breathing data is missing the model 332 
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makes no prediction for tumor location. This can be clearly seen in the long period of missing 333 
data around 30s, and also in the much shorter periods around 19s and 62s. In all cases, we 334 
have plotted an interpolated solid line for the model data for consistency with other plots, 335 
although in actual fact the model makes no prediction at those times of missing breathing 336 
data. 337 
 338 
The RMS error for this beam data is 1.09 mm and the correlation coefficient is 0.98. The 339 
band width for 95% residency is 2.1 mm. These results indicate that the model deals well 340 
with irregularities in the data. Figure 6 below shows the histogram of residuals and the 341 
regression plot for the data presented in Figure 5. The tail of negative residuals in this 342 
histogram is long relative to those shown in Figure 4. This is not due to poor systematic 343 
performance but rather due to the performance in the short recovery period immediately 344 
following the spike in Figure 5, lasting less than one second. 345 
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 347 
Figure 6: Residual plot (left) and regression plot (right) for Patient 8, Day 2, Beam 1. The 348 
mean is -0.030 and standard deviation 1.09, while the correlation coefficient is 0.98. 349 
 350 
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4. Discussion 351 
A modified version of the Wilson & Meyer spring-dashpot model has been developed to 352 
correlate abdominal motion with lung tumor motion. In its current implementation the 353 
approach is capable of modeling the main component of tumor motion in the SI direction. 354 
The model was applied to clinical tumor tracking data from 10 patients treated on the 355 
Mitsubishi Real-Time Radiation Therapy system in Sapporo, Japan. In the first stage, the 356 
model parameters were optimized for each individual beam in order to determine the 357 
goodness of fit for each data set. These values served as a benchmark for further evaluation 358 
in Stage 2. In Stage 2, the optimized model parameters for one particular beam were used to 359 
estimate the output, i.e. tumor motion, for other beams and treatment days in order to 360 
evaluate the trade-offs with regard to optimizing each individual beam separately. The 361 
motivation for this was to find out whether it is possible for model parameters to be 362 
determined on the first day of treatment or even prior to treatment. The average error 363 
determined for Stage 1 was 0.90 ± 0.40 mm, which increased by 0.37 mm in Stage 2. The 364 
results were very similar if parameters were used that were initially estimated for other 365 
beams for the same patient. This indicates that despite the temporal changes in the 366 
abdominal/tumor motion relationship over a treatment course the physical characteristics 367 
remain fairly constant, which is reflected in only a small increase in the residual error. This is 368 
the advantage of a semi-physical model, such as the one presented here, which aims to 369 
model the tissue elasticity as opposed other models which might provide an excellent fit to 370 
the input/output data but have no intrinsic relationship to the actual mechanical tissue 371 
properties. 372 
To put the results into a more clinically relevant context, hypothetical bounds were calculated 373 
so that the modeled point location of the tumor would be within the actual point location of 374 
the tumor for 95% of the treatment time. This hypothetical bound would account for the 375 
inaccuracies of the modeling and assumes otherwise perfect compensation of the tumor 376 
motion, by tumor tracking or respiratory gating, for example. The bound calculated for stage 377 
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1 averaged over 52 beams was 2.0 mm and for Stage 2 it was 2.6 mm. To obtain a better 378 
understanding of the variability within the patients, three representative patients were further 379 
analyzed, patients 7, 8 and 10, corresponding to a residual error of 0.95 mm (‘mean’), 1.61 380 
mm (poor’) and 0.84 mm (‘excellent’) in Stage 1. The residual errors showed a largely 381 
Gaussian distribution with minimal offset from the mean indicating that the model did not 382 
result in systematic model output errors. The calculated error bounds based on the 95% 383 
inclusion criteria calculated for the selected patients were 2.1, 3.0, 1.7 mm, respectively, 384 
which gives an indication of the correlation between the residual modeling errors and the 385 
resulting position uncertainty, which ultimately feeds into the calculation of appropriate 386 
margins. 387 
One of the useful features of the spring-dashpot system is that it managed to successfully 388 
model baseline drifts and irregular tumor motion. It was also capable of quickly restoring 389 
accurate model output when data was missing as shown in Figure 5. The determination of 390 
optimal modeling parameters did not include a systematic search of the global parameter 391 
space; a downhill search algorithm was used for efficiency. It remains to be investigated if a 392 
stochastic search technique, e.g. simulated annealing or approximate Bayesian 393 
computation, is required to remove dependence on the initial parameter estimates, but this 394 
will be at the expense of higher computational costs. For consistency the initial starting 395 
condition for the search was kept constant but it was found that the nominal values of the 396 
optimized parameters diverged if different starting conditions were used (data not shown). 397 
However, it was found that the resulting residuals were almost identical, which indicates that 398 
the solution space is relatively flat. Therefore it was not considered critical but remains an 399 
area of further investigation. 400 
For clinical implementation, several extensions to the current modeling process are needed. 401 
One is the extension to a full three dimensional system which also considers the minor axes 402 
of tumor motion (AP and lateral) for the sake of completeness for the proportion of patients 403 
where this motion is non-negligible. Also, ideally the system should be predictive, as there is 404 
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a finite time required for the treatment machinery (couch8 or multi-leaf collimator12) to adjust 405 
to the determined change in position. Ultimately, any algorithm has limitations and is 406 
dependent on the quality of the input data and therefore the output of the model should be 407 
tested and verified with independent means in a clinical setting. 408 
 409 
5. Conclusion  410 
A semi-physical spring-dashpot model to correlate breathing to tumor motion in the superior-411 
inferior direction has been presented and applied to clinical tracking data. Optimized model 412 
parameters were found to be robust and transferrable to different beams on the same day 413 
and consecutive days. Day-to-day variations in the agreement between the model output 414 
and the measured data were small, indicating that the model parameters may be determined 415 
prior to or on the first day of treatment and then used throughout the course of treatment. 416 
The semi-physical nature of the model enabled it to deal with irregularities in the data such 417 
as baseline drifts, phase shifts and amplitude and frequency variations. Further work will 418 
address the expansion of the model to include all three dimensions and experimental testing 419 
and verification of the model output in a clinical setting. 420 
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